Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy
Authors:
- Marcia L. StefanickMSMarcia L. Stefanick
- Garnet L. AndersonGAGarnet L. Anderson
- Karen L. MargolisKMKaren L. Margolis
- Susan L. HendrixSHSusan L. Hendrix
- Rebecca J. RodaboughRRRebecca J. Rodabough
- Electra D. PaskettEPElectra D. Paskett
- Dorothy S. LaneDLDorothy S. Lane
- F. Allan HubbellFHF. Allan Hubbell
- Annlouise R. AssafAAAnnlouise R. Assaf
- Gloria E. SartoGSGloria E. Sarto
- Robert S. SchenkenRSRobert S. Schenken
- Shagufta YasmeenSYShagufta Yasmeen
Top Cited Papers
Open Access
- 12 April 2006
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 295 (14) , 1647-1657
Abstract
In the Women's Health Initiative (WHI) randomized Estrogen plus Progestin (E + P) trial in postmenopausal women, oral conjugated equine estrogens (CEE) combined with medroxyprogesterone acetate produced more health risks than benefits,1 including a higher incidence of invasive breast cancers, which were diagnosed at a more advanced stage, and a substantially greater proportion of abnormal mammograms compared with placebo.2 The parallel WHI Estrogen-Alone trial, which randomized women with prior hysterectomy to CEE only or placebo, was stopped early based on available data representing an average of 6.8 years of follow-up because of increased stroke incidence and no reduction in risk of coronary heart disease.3 In contrast to substantial epidemiological evidence associating exogenous estrogens with increased breast cancer incidence,4-9 preliminary analyses found fewer breast cancers in women in the CEE group, prompting a detailed updated analysis of breast cancer incidence and mammographic reports. The completed trial results reported herein include all events occurring prior to the stopping of the intervention and unblinding. Biologically plausible explanations for the possibility of decreased incidence of breast cancer with CEE are considered and examined in exploratory analyses, including interactions of treatment assignment with baseline risk factors.Keywords
This publication has 31 references indexed in Scilit:
- Intrinsic Mechanism of Estradiol-Induced Apoptosis in Breast Cancer Cells Resistant to Estrogen DeprivationJNCI: Journal of the National Cancer Institute, 2005
- The WHI Estrogen-Alone Trial—Do Things Look Any Better?JAMA, 2004
- Long-Term Exposure to Tamoxifen Induces Hypersensitivity to EstradiolClinical Cancer Research, 2004
- The endocrine management of postmenopausal women with early breast cancer.Breast Cancer, 2004
- Changing role of the oestrogen receptor in the life and death of breast cancer cellsThe Breast, 2003
- Prognostic Characteristics of Breast Cancer Among Postmenopausal Hormone Users in a Screened PopulationJournal of Clinical Oncology, 2003
- Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women’s Health Initiative Randomized TrialObstetrical & Gynecological Survey, 2003
- Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus ProgestinJNCI: Journal of the National Cancer Institute, 2000
- Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast CancerJNCI: Journal of the National Cancer Institute, 1999
- The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal WomenNew England Journal of Medicine, 1995